GlassScriptPhysician profile
Vicki B Latham-Solomon
NPI 1023205515
$1,520.82
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $91.99 · 2021: $139 · 2022: $317 · 2023: $557 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $299.00 | 2022-2024 | Zepbound, Trulicity, Mounjaro |
| Novo Nordisk INC | $252.07 | 2019-2023 | Wegovy |
| Abbott Laboratories | $226.96 | 2022-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $89.39 | 2019-2023 | Breztri, Farxiga |
| Abbvie INC. | $79.37 | 2022-2023 | |
| Amgen INC. | $76.97 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $53.67 | 2021-2023 | |
| Boston Scientific Corporation | $36.90 | 2019 | |
| Pfizer INC. | $36.70 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.65 | 2021-2022 | |
| Horizon Therapeutics Plc | $33.32 | 2023 | Krystexxa |
| Astellas Pharma US INC | $26.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.76 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.43 | 2023 | Uptravi, Opsumit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.42 | 2021 | |
| Shire North American Group INC | $20.57 | 2019 | |
| Edwards Lifesciences Corporation | $19.87 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.15 | 2022 | |
| Glaxosmithkline, LLC. | $16.41 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.45 | 2023 | Onpattro |
| Ironwood Pharmaceuticals, INC | $14.67 | 2021 | |
| Mylan Specialty L.P. | $14.47 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $13.57 | 2019 | |
| Insulet Corporation | $13.52 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.38 | 2021 | |
| Amarin Pharma, INC. | $13.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Latham-Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.